|
Red blood cell infected with P.vivax
Malaria (Italian bad air; formerly called ague in English) is
a tropical infectious disease which causes about half a
billion infections and two million deaths annually, mainly in tropical countries and
especially in sub-Saharan Africa. The protozoan cause of malaria was discovered by a French army doctor, Charles Louis Alphonse Laveran, for which he was awarded the Nobel Prize for Physiology or
Medicine in 1907.
Malaria is caused by the protozoan parasite Plasmodium (one of the Apicomplexa) - the
main culprits are P. falciparum and P. vivax, but P. ovale and P. malariae are also known to
cause malaria. The vector for the malarial parasite is the
Anopheles mosquito.
Symptoms of malaria include fever, shivering, arthralgia (joint pain), vomiting, and convulsions. There may be the feeling of tingling in the skin, particularly with malaria caused by P.
falciparum. Complications of malaria include coma and death if untreated - young
children are especially vulnerable.
Mechanism of the disease
Infected female Anopheles mosquitos carry Plasmodium sporozoites in their salivary glands. If they
bite a person, which they usually do starting at dusk and during the night, the sporozoites enter the person's body via the
mosquito's saliva, migrate to the liver where they multiply within hepatic liver cells.
They then turn into merozoites which
then enter red blood cells. There they multiply further, periodically
breaking out of the red blood cells. The classical description of waves of fever coming every three or four days arises from
simultaneous waves of merozoites breaking out of red blood cells during the same day.
The parasite is relatively protected from attack by the body's immune
system because it stays inside liver and blood cells. However, circulating infected blood cells are killed in the spleen. To avoid this fate, the parasite produces certain surface proteins which infected blood cells express on their cell surface, causing the blood cells to stick to the
walls of blood vessels. These surface proteins are highly variable and cannot serve as a reliable target for the immune system.
The stickiness of the red blood cells are particularly pronounced in P. falciparum malaria and this is the main factor
giving rise to hemorrhagic complications of malaria.
Some merozoites turn into male and female gametocytes. If a mosquito bites the infected person and picks up gametocytes with the blood, fertilization
occurs in the mosquito's gut, new sporozoites develop and travel to the mosquito's salivary gland, completing the cycle.
Pregnant women are especially attractive to the mosquitos, and malaria in pregnant women is an important cause of still births
and infant mortality.
Treatment and prevention
If diagnosed early, malaria can be treated, but prevention is always much better, and substances that inhibit the parasite are
widely used by visitors to the tropics. Since the 17th century quinine has been the prophylactic of choice for malaria. The development of quinacrine, chloroquine, and primaquine in the 20th century reduced the reliance on quinine. These anti-malarial medications can
be taken preventively, which is recommended for travellers to affected regions.
Certain strains of Plasmodium have recently developed resistance to chloroquine which has been the first line of
treatment in many countries, thus complicating the treatment. In west Africa, where the local strains of malaria are particularly
virulent, Lariam is now the recommended
prophylactic, despite causing psychological problems in some vulnerable people. It seems inevitable that resistance to this will
also occur.
In addition to the antimalarial drugs, the use of mosquito repellents such as DEET, and
mosquito nets and screens can reduce the chance of malaria, as well as the discomfort of insect bites.
Extracts from the plant Artemisia (specifically Artemisia annua), containing the compound artemisinin, a substance unrelated to the quinine derivatives, offer some future promise.
Prospects of disease control
Vaccines for malaria are under development, but no effective vaccine exists as of 2003.
It is hoped that the genome sequence of the most deadly agent of malaria,
Plasmodium falciparum, which was completed in 2002, will provide targets for new
drugs or vaccines.
Efforts to eradicate malaria by attacking mosquitos have been successful in some areas. Malaria was once common in the
United States and southern Europe, but the draining of wetland breeding grounds and better sanitation eliminated it from affluent regions.
Malaria was eliminated from the northern parts of the USA in the early twentieth century, and the use of the pesticide DDT during the 1950s eliminated it from the south.
A major public health effort to eradicate malaria by selectively targeting mosquitos in areas where malaria was rampant was
embarked upon in the 1950s and 1960s. (The Mosquito Killer - PDF of the same
article )
Since most of the deaths today occur in poor rural areas of Africa without health care, the distribution to children of
mosquito nets impregnated with insect repellants has been suggested as the most cost-effective prevention method. These nets can
often be obtained for less than US$10 or 10 euros when purchased in bulk from the United Nations or other organizations.
Some advocates believe that DDT spraying is even cheaper and more effective than nets, and charge that environmentalists have
created perverse restrictions on DDT use that have multiplied African malaria deaths into the millions in countries where the
disease had been all but eradicated.
Sickle cell anemia and other genetic effects
Carriers of the sickle cell anaemia gene are protected
against malaria because of their particular hemoglobin mutation; this explains why
sickle cell anemia is particularly common among people of African origin. There is a theory that another hemoglobin mutation,
which causes the genetic disease thalassemia, may also give its carriers an
enhanced immunity to malaria.
Another disease that gives protection against malaria is G6PD (glucose-6-phosphate dehydrogenase deficiency). It protects against
malaria caused by Plasmodium falciparum as the presence of this enzyme is critical to survival of these parasites within
red blood cells.
It is thought that humans have been afflicted by malaria for about 8,000 years, and several human genes responsible for blood
cell proteins and the immune system have been shaped by the struggle against the parasite.
External links
- Nature Science Update Malaria special
|